Stocks of ADMA Biologics Inc. (NASDAQ:ADMA) traded higher last session on Wall Street, up 2.17% to $3.77.
ADMA stock price is now 7.67% away from the 50-day moving average and 44.30% away from the 200-day moving average. The market capitalization of the company currently stands at $820.99M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
With the price target of $5, Mizuho recently initiated with Buy rating for ADMA Biologics Inc. (NASDAQ: ADMA). On November 11, 2021, Raymond James Upgraded its previous ‘Outperform’ rating to ‘Strong Buy’ on the stock keeping its target price maintained at $5, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’.
In other news, Grossman Adam S, President and CEO bought 14,982 shares of the company’s stock on Dec 09. The stock was bought for $42,849 at an average price of $2.86. Upon completion of the transaction, the President and CEO now directly owns 1,143,426 shares in the company, valued at $4.31 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 09, President and CEO Grossman Adam S bought 14,983 shares of the business’s stock. A total of $42,851 was incurred on buying the stock at an average price of $2.86. This leaves the insider owning 2,203,708 shares of the company worth $8.31 million. Insiders disposed of 551,546 shares of company stock worth roughly $2.08 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ADMA stock. A new stake in ADMA Biologics Inc. shares was purchased by FRED ALGER MANAGEMENT, LLC during the first quarter worth $10,798,000. TANG CAPITAL MANAGEMENT LLC invested $3,743,000 in shares of ADMA during the first quarter. In the first quarter, RAFFERTY ASSET MANAGEMENT, LLC acquired a new stake in ADMA Biologics Inc. valued at approximately $2,186,000. FEDERATED HERMES, INC. acquired a new stake in ADMA for approximately $1,229,000. QUBE RESEARCH & TECHNOLOGIES LTD purchased a new stake in ADMA valued at around $1,104,000 in the second quarter. In total, there are 165 active investors with 67.30% ownership of the company’s stock.
Wednesday’s opening bell rang with an opening price of $3.7000 for ADMA Biologics Inc. (NASDAQ: ADMA). During the past 12 months, ADMA Biologics Inc. has had a low of $1.38 and a high of $3.98. As of last week, the company has a debt-to-equity ratio of 1.41, a current ratio of 5.00, and a quick ratio of 1.40. The fifty day moving average price for ADMA is $3.5016 and a two-hundred day moving average price translates $2.6126 for the stock.
The latest earnings results from ADMA Biologics Inc. (NASDAQ: ADMA) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.07, beating analysts’ expectations of -$0.08 by 0.01. This compares to -$0.13 EPS in the same period last year. The net profit margin was -53.90% and return on equity was -58.30% for ADMA. The company reported revenue of $41.09 million for the quarter, compared to $20.68 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 98.68 percent. For the current quarter, analysts expect ADMA to generate $34.48M in revenue.
ADMA Biologics Inc.(ADMA) Company Profile
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
